In Conversation: Gary Fanger, Ph.D., Founder, President, and CEO of Rise Therapeutics

Published on :

In the context of normal human biology, the microbiome is a collection of microorganisms, including bacteria, fungi, viruses, and other microbes, that reside in various bodily habitats, including our gut. Gary Fanger, Founder, President and Chief Executive Officer of Rockville-based Rise Therapeutics, explains that the microbiome needs to be seen in light of a new organ in the body.

In Conversation: Akshay Kapadia, Founder and Chief Executive Officer at Conexus Solutions

Published on :

Conexus was launched in 2016, with the goal of providing outsourced commercial operations for pharmaceutical and life sciences companies. Conexus primarily focuses on the small and mid-size market, which has been somewhat ignored by other service providers, Chief Executive Officer and Founder, Akshay Kapadia told BioBuzz.

In Conversation: Jeff Caskey, Biotech Recruiting Manager, WorkForce Genetics

Published on :

We caught up with Jeff Caskey of WorkForce Genetics (WFGX), a leading life sciences recruiting search firm, to discuss his professional journey, why recruiting became his passion, and how he’s managed to achieve work-life balance despite the rigorous demands of his profession.

In Conversation: Shannon Biermann, Senior Quality Control Manager – Microbiology at NextCure

Published on :

BioBuzz recently spoke with Shannon Biermann, who is a Senior Quality Control Manager of Microbiology at Beltsville, MD-based NextCure, to learn more about how she’s navigated her career in Microbiology QC thus far and how NextCure’s unique company culture helped her to take ownership and propel her career to the next level.

In Conversation: Bill Snider, Partner at BroadOak Capital Partners

Published on :

For many life sciences companies, access to capital can be difficult at times. However, where there may be obstacles, opportunities can be found. That’s the philosophy of BroadOak Capital Partners’ Bill Snider, who leads the Bethesda, Maryland-based firm’s growth capital investing activities. One of the founders of BroadOak, Snider said the firm’s vision has been to be something of a merchant bank, providing financial support and advice for the tools and diagnostics products companies operating in the life sciences. As a modern-day merchant bank, Snider said the firm wanted to be flexible in order to provide the best advice for their clients. Clients include those companies that focus on research tools and consumables, diagnostics, biopharma services, and adjacent markets.

In Conversation: David Vanik, Ph.D., Partner at McBee Moore & Vanik IP

Headshot of David Vanik of MMVIP
Published on :

Since the days of working on his Ph.D. in protein science, David Vanik has had an interest in intellectual property and patent law. As Vanik closed in on completing his doctoral research, he began to look at IP within the area of biotechnology.

In Conversation: Matthew Hewitt, Ph.D., Executive Director at Charles River Laboratories

Published on :

If you’re a scientist, chances are when you hear the name “Charles River Laboratories” (Charles River) you may initially think of their industry-leading research models which are a staple for research labs globally. But did you also know that Charles River offers a plethora of products and services for translational laboratories and life science companies alike that span across the drug development lifecycle?

In Conversation: Thomas Blake and Alison Demarest of Meridian BioGroup

Published on :

This year, Meridian BioGroup of Frederick, Maryland is celebrating its 15th year in business. The compliance, validation, and regulatory services provider has grown substantially in that time, and continues to put in the work to expand and improve. Co-founders Thomas Blake and Alison Demarest take pride in the work of their employees, Meridian’s work culture, and the expertise of the company in the biotech and pharmaceutical fields.

In Conversation: John Mumm, Chief Executive Officer, Deka Biosciences

Published on :

John Mumm is a serial biotechnology entrepreneur who, as a young researcher, demonstrated the importance of the cytokine, interleukin -10 (IL-10), in activating the immune system to destroy tumors. That research led to the use of Pegylated IL-10 to treat patients with pancreatic cancer and other solid tumors through his work at ARMO Biosciences, a company he founded and was later acquired by Eli Lilly in 2018.

In Conversation: Douglas Falk, Chief Executive Officer, Vita Therapeutics

Douglas Falk
Published on :

Vita Therapeutics, freshly infused with $32 million in financing, is advancing a novel approach to treating a localized form of muscular dystrophy with a cell therapy that combines a gene correction and induced pluripotent stem cell (iPSC) technology.